中商官网
数据库
前沿报告库
Global Human Respiratory Syncytial Virus Drugs Market 2018 Forecast to 2023
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.Scope of the Report:
This report focuses on the Human Respiratory Syncytial Virus Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period.
The active participation of emerging economies toward research and development will drive the growth prospects for the market during the forecast period. The increasing R&D activities in emerging economies for RSV infection and its causes will fuel the development of novel drugs. One of the major factors responsible for the market’s growth is the rising amount of patented therapies for RSV treatment that result in substantial R&D activities from various big pharma companies and research institutes. For instance, in June 2016, the Lancet Respiratory Medicine reported that RSV was the most commonly detected pathogen linked with pneumonia among children in South Africa. Such new findings will increase the scope of anti-RSV drugs in new applications, such as pneumonia.
ROW accounted for the maximum market share during 2017 and continue to dominate the market for the next few years. One of the major factors responsible for the market’s growth in the region is the growing incidence of RSV infections in ROW, including the BRIC nations.
The worldwide market for Human Respiratory Syncytial Virus Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.Market Segment by Manufacturers, this report covers
AstraZeneca
AbbVie
GSK
Teva PharmaceuticalMarket Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)Market Segment by Type, covers
Approved Drugs
Off-Label DrugsMarket Segment by Applications, can be divided into
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories HospitalsThere are 15 Chapters to deeply display the global Human Respiratory Syncytial Virus Drugs market.
Chapter 1, to describe Human Respiratory Syncytial Virus Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Human Respiratory Syncytial Virus Drugs, with sales, revenue, and price of Human Respiratory Syncytial Virus Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Human Respiratory Syncytial Virus Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Human Respiratory Syncytial Virus Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Human Respiratory Syncytial Virus Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
本报告所有内容受法律保护，中华人民共和国涉外调查许可证：国统涉外证字第1454号。 本报告由中商产业研究院出品，报告版权归中商产业研究院所有。本报告是中商产业研究院的研究与统计成果，报告为有偿提供给购买报告的客户内部使用。未获得中商产业研究院书面授权，任何网站或媒体不得转载或引用，否则中商产业研究院有权依法追究其法律责任。如需订阅研究报告，请直接联系本网站，以便获得全程优质完善服务。 本报告目录与内容系中商产业研究院原创，未经本公司事先书面许可，拒绝任何方式复制、转载。 在此，我们诚意向您推荐鉴别咨询公司实力的主要方法。
近日，中商产业研究院专家团队赴滁州市开展《滁州市制造业数字化、网络化、智能化、绿色化发展的堵点及对策...
近日，中商产业研究院专家团队赴滁州市开展《滁州市制造业数字化、网络化、智能化、绿色化发展的堵点及对策...
查看详情
2024年12月27日，昆明市发展和改革委员会组织召开《“十五五”时期提升昆明服务业竞争力对策研究》专家评审...
2024年12月27日，昆明市发展和改革委员会组织召开《“十五五”时期提升昆明服务业竞争力对策研究》专家评审...
查看详情
12月25日，2024年全国农业产业高质量发展大会暨2024年全国农业产业投资推介会在深圳市隆重开幕。此次盛会以...
12月25日，2024年全国农业产业高质量发展大会暨2024年全国农业产业投资推介会在深圳市隆重开幕。此次盛会以...
查看详情
近日，广东省云浮市政府党组成员、佛山市-云浮市对口帮扶协作指挥部指挥长，佛云园党工委书记、管委会主任...
近日，广东省云浮市政府党组成员、佛山市-云浮市对口帮扶协作指挥部指挥长，佛云园党工委书记、管委会主任...
查看详情
近日，湖北省随州市人民政府党组成员刘军伟一行莅临我院考察交流，会上刘军伟介绍了随州市的产业基础及现状...
近日，湖北省随州市人民政府党组成员刘军伟一行莅临我院考察交流，会上刘军伟介绍了随州市的产业基础及现状...
查看详情
12月18日，由贵州省人民政府驻广州办事处主办的省驻粤招商工作基金招商专题培训会在深圳中商产业研究院项目...
12月18日，由贵州省人民政府驻广州办事处主办的省驻粤招商工作基金招商专题培训会在深圳中商产业研究院项目...
查看详情
12月13日下午，河北省发展和改革委员会规划处、人事处组织开展发改大讲堂“十五五”规划编制系列专题培训，...
12月13日下午，河北省发展和改革委员会规划处、人事处组织开展发改大讲堂“十五五”规划编制系列专题培训，...
查看详情
2024年12月9日，内蒙古鄂尔多斯市创新资本招商培训班在深圳举办，中商产业研究院袁健教授应邀为培训班学员...
2024年12月9日，内蒙古鄂尔多斯市创新资本招商培训班在深圳举办，中商产业研究院袁健教授应邀为培训班学员...
查看详情
立即购买
专家咨询
下载订购表
word下载
按需定制
简繁转换
在线咨询
